Literature DB >> 8194873

Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha).

N Renard1, D Liénard, L Lespagnard, A Eggermont, R Heimann, F Lejeune.   

Abstract

Twenty-seven patients treated with high-dose rTNF alpha, IFN gamma and melphalan by isolated limb perfusion were histologically documented. There were 20 cases of melanoma-in-transit metastases and 7 cases of high-grade soft-tissue sarcoma. Biopsies were taken before IFN gamma, after IFN gamma, before TNF alpha and between 2 hr and 60 days after the TNF alpha perfusion. Immunohistochemistry was performed for adhesion molecules ICAM-I, ELAM-I (E selectin), VCAM-I and PECAM. During the first hours after beginning perfusion, the endothelial cells of the tumour capillaries appeared swollen. Significant tumour necrosis was already observed 3 hours after the perfusion in melanoma cases. The overall predominant feature was coagulative necrosis associated or not with haemorrhagic necrosis. TNF alpha induced increased expression of ELAM-I and VCAM-I adhesion molecules on intratumoral endothelial cells. The activated tumour vessels were progressively destroyed. Significant intravascular recruitment of polymorphonuclear cells (PMNs) was observed 3 hr after starting TNF alpha; it was followed by diapedesis and tumour colonization 3 days later. T lymphocytes and macrophages were detected during the first 7 days and B lymphocytes during the second week. Melanoma in transit metastases treated with alkylating agent alone did not show significant necrosis and did not express high levels of adhesion molecules (ELAM-I, VCAM-I) nor infiltration by PMN.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8194873     DOI: 10.1002/ijc.2910570508

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

Review 1.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

2.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.

Authors:  M G van Ijken; E A de Bruijn; G de Boeck; T L ten Hagen; J R van der Sijp; A M Eggermont
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

Review 3.  Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy.

Authors:  G Molema; L F de Leij; D K Meijer
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

4.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.

Authors:  A M Eggermont; H Schraffordt Koops; J M Klausner; B B Kroon; P M Schlag; D Liénard; A N van Geel; H J Hoekstra; I Meller; O E Nieweg; C Kettelhack; G Ben-Ari; J C Pector; F J Lejeune
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

5.  Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.

Authors:  Michael Kragh; Bjørn Quistorff; Michael R Horsman; Paul E G Kristjansen
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

6.  Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

Authors:  Anna Johansson; Juliana Hamzah; Christine J Payne; Ruth Ganss
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

7.  One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.

Authors:  Dirk J Grünhagen; Flavia Brunstein; Wilfried J Graveland; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

8.  Expression, purification, and characterization of recombinant protein GX1-rmhTNFalpha.

Authors:  Shanshan Cao; Yan Liu; Xiaohua Li; Yingqi Zhang; Jun Wang; Wenqi Du; Yu Han; Haifeng Jin; Lina Zhao; Kaichun Wu; Daiming Fan
Journal:  Mol Biotechnol       Date:  2009-04-09       Impact factor: 2.695

9.  Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results.

Authors:  Catherina S P van Rijswijk; Maartje J A Geirnaerdt; Pancras C W Hogendoorn; Johannes L Peterse; Frits van Coevorden; Antonie H M Taminiau; Rob A E M Tollenaar; Bin B R Kroon; Johan L Bloem
Journal:  Eur Radiol       Date:  2003-01-08       Impact factor: 5.315

Review 10.  Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.

Authors:  Cornelis Verhoef; Johannes H W de Wilt; Dirk J Grünhagen; Albertus N van Geel; Timo L M ten Hagen; Alexander M M Eggermont
Journal:  Curr Treat Options Oncol       Date:  2007-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.